Secondary Outcomes
ADVERSE EFFECTS, DISEASE, PCT
Overall 14-, 28- and 60-day survival rates were 87.8% (130/148 patients, data for four patients were unavailable), 71.3% (102/143 patients, data for nine patients were unavailable) and 66.4% (83/125 patients, data for 14 patients were unavailable), respectively. There was no statistically significant difference in neither of these survival rates between the two groups.The median number of days spent in the ICU for both groups was 13 (IQR 9–20) and the median number of days in the hospital was 19 (IQR 14–26). The median PaORegarding vitamin D supplementation, the mean vitamin D level on admission was 27.1 ± 12.4 nmol/L. The mean vitamin D level for the intervention group on admission was 27.23 ± 11.8 nmol/L. There was no difference between the two groups (Analysis of disease severity markers showed differences in trends for CRP, PCT and neutrophil/lymphocyte ratio. Patients in the intervention group had delayed increases in CRP and PCT plasma levels and also in neutrophil/lymphocyte ratio compared to the control group. However, there were no significant differences between the two groups. Results are shown in No adverse effects attributable to vitamin D supplementation were observed during this study. None of the patients in the intervention group met exclusion criteria.